The Italian Competition Authority obliges a pharmaceutical company to grant a drug production license (Glaxo - Principi attivi)

On 8 February 2006, the Italian Antitrust Authority (IAA) closed a one-year long Article 82 investigation in relation to Glaxo refusal to grant a production license to FIS (Fabbrica Italiana Sintetici), for manufacturing in Italy an active compound essential for the production of triptans cluster migraine drugs. In 2002 FIS applied to the Italian Ministry of Productive Activities in order to obtain from Glaxo a Complementary Protection Certificate (CPC) authorizing the production of a certain chemical substance. FIS needed the CPC to start manufacturing the compound since Glaxo holds a patent right on such intermediate product in the EU with the exception of Spain. Glaxo refused to license the

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Freshfields Bruckhaus Deringer (Rome)

Quotation

Gian Luca Zampa, The Italian Competition Authority obliges a pharmaceutical company to grant a drug production license (Glaxo - Principi attivi), 8 February 2006, e-Competitions February 2006, Art. N° 535

Visites 4842

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues